{"id":907560,"date":"2025-11-10T17:27:10","date_gmt":"2025-11-10T22:27:10","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/soligenix-announces-recent-accomplishments-and-third-quarter-2025-financial-results\/"},"modified":"2025-11-10T17:27:10","modified_gmt":"2025-11-10T22:27:10","slug":"soligenix-announces-recent-accomplishments-and-third-quarter-2025-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/soligenix-announces-recent-accomplishments-and-third-quarter-2025-financial-results\/","title":{"rendered":"Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n
\n PRINCETON, N.J.<\/span>
\n <\/span>, Nov. 7, 2025<\/span><\/span> \/PRNewswire\/ —\u00a0Soligenix, Inc.<\/a>\u00a0(Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need,\u00a0announced today its recent accomplishments and financial results for the quarter ended September 30, 2025<\/span>.<\/p>\n

\n

\n
\n \"(PRNewsfoto\/Soligenix,
\n <\/a>\n <\/p>\n<\/p><\/div>\n

“We remain focused on multiple upcoming milestones before year-end, including top-line results from our Phase 2a clinical trial in mild-to-moderate psoriasis with SGX302 (synthetic hypericin) and an enrollment update for the confirmatory Phase 3 study evaluating\u00a0HyBryte\u2122 (synthetic hypericin) in the treatment of cutaneous T-cell lymphoma (CTCL),” stated Christopher J. Schaber<\/span>, PhD, President and Chief Executive Officer of Soligenix. “Recently, we were pleased to announce that the first Data Monitoring Committee (DMC) meeting for the confirmatory Phase 3 study evaluating HyBryte\u2122 in the treatment of CTCL had concluded that there were no safety concerns, with HyBryte\u2122 demonstrating an acceptable safety profile that remains consistent with the safety data from all prior clinical studies. Looking ahead to 2026, Phase 3 enrollment remains on track with top-line results anticipated in the second half of 2026.”<\/p>\n

Dr. Schaber continued, “With approximately $10.5 million<\/span> in cash at September 30, 2025<\/span>, we’re focused on carefully allocating resources to hit our strategic goals and upcoming milestones. While this cash balance provides sufficient operating runway through 2026, we continue to evaluate all strategic options, including partnership, merger and acquisition, government grants, and potential financing opportunities to advance our late-stage pipeline and the Company.”<\/p>\n

\n Soligenix Recent Accomplishments<\/b>\n <\/p>\n